Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard S Foster

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University HospitalDeQuincy A Lewis, Mark Tann, Kenneth Kesler, et al.
Urologic Oncology|February 1, 2020
Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?Adam C Calaway, Richard S Foster, Yan Tong, et al.
The Urologic Clinics of North America|May 9, 2007
Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcomeStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
The Journal of Urology|April 18, 2009
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgeryStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissectionStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
The Journal of Urology|June 15, 2007
Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patientsStephen D W Beck, Matthew D Peterson, Richard Bihrle, et al.
Urologic Oncology|November 23, 2005
Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancerStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Cancer|August 1, 2007
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?Stephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?Yaron Ehrlich, Mary J Brames, Stephen D W Beck, et al.
The American Journal of Surgical Pathology|April 24, 2004
Nephroblastoma arising in a germ cell tumor of testicular originRobert E Emerson, Thomas M Ulbright, Shaobo Zhang, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University HospitalDeQuincy A Lewis, Mark Tann, Kenneth Kesler, et al.
Urologic Oncology|February 1, 2020
Improving postoperative quality of care in germ cell tumor patients: Does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?Adam C Calaway, Richard S Foster, Yan Tong, et al.
The Urologic Clinics of North America|May 9, 2007
Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcomeStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
The Journal of Urology|April 18, 2009
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgeryStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissectionStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
The Journal of Urology|June 15, 2007
Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patientsStephen D W Beck, Matthew D Peterson, Richard Bihrle, et al.
Urologic Oncology|November 23, 2005
Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancerStephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Cancer|August 1, 2007
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?Stephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?Yaron Ehrlich, Mary J Brames, Stephen D W Beck, et al.
The American Journal of Surgical Pathology|April 24, 2004
Nephroblastoma arising in a germ cell tumor of testicular originRobert E Emerson, Thomas M Ulbright, Shaobo Zhang, et al.
Pageof 12